Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

(2016) Ludwig Kappos et al.   LANCET NEUROLOGY

The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Experimental design and analysis and their reporting: new guidance for publication in BJP

(2015) Michael J Curtis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP

(2015) John C McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

445 The TOUCHSTONE Study: A Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis

(2015) William Sandborn et al.   GASTROENTEROLOGY

The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue

(2015) Emmanuel E. Egom et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

(2015) Christopher Southan et al.   NUCLEIC ACIDS RESEARCH

Sa1222 Results of a Safety and Tolerability Study of Rpc1063, a Novel Orally Administered Sphingosine-1-Phosphate Receptor 1 (S1p1r) Agonist, in Healthy Adult Volunteers

(2015) Allan Olson et al.   GASTROENTEROLOGY

Sa1221 Rpc1063, a Potent, Selective S1P1 Receptor Modulator, Is Active in a Therapeutic IBD Model and Exhibits Favorable PK/PD Properties in Healthy Volunteers

(2015) Jennifer Brooks et al.   GASTROENTEROLOGY

Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications

(2014) John Camm et al.   AMERICAN HEART JOURNAL

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial

(2014) Andrea Vaclavkova et al.   LANCET

Second generation S1P pathway modulators: Research strategies and clinical developments

(2013) Marc Bigaud et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1receptor modulator, in the first-in-human study

(2013) Patrick Brossard et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

(2013) Krzysztof Selmaj et al.   LANCET NEUROLOGY

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

(2012) P Gergely et al.   BRITISH JOURNAL OF PHARMACOLOGY

Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers

(2011) Robert Schmouder et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Fingolimod for the treatment of relapsing multiple sclerosis

(2010) Douglas R Jeffery et al.   Expert Review of Neurotherapeutics

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE